DaVita vs Labcorp
Labcorp reported revenue of $14.0 billion in fiscal 2025, about the same as DaVita's $13.6 billion in fiscal 2025. DaVita's revenue grew 6.5% in its latest year, and Labcorp's grew 7.2%. DaVita had an operating margin of 15.0%, against 9.9% at Labcorp. Free cash flow was $1.3 billion at DaVita and $1.2 billion at Labcorp.
Side by side
| DaVita | Labcorp | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $13.6B | $14.0B |
| Revenue growth | 6.5% | 7.2% |
| Revenue growth a year, last 5 years | 3.4% | −0.0% |
| Gross margin | — | 28.8% |
| Operating margin | 15.0% | 9.9% |
| Net margin | 5.5% | 6.3% |
| Free cash flow | $1.3B | $1.2B |
| Free cash flow margin | 9.6% | 8.6% |
| Return on capital | 17.6% | 8.2% |
| Net debt to EBITDA | 3.5x | 2.5x |
| Dividends and buybacks | $1.3B | $691M |
| Change in diluted share count | −13.1% | −0.7% |
| Last close | $184.03 | $329.90 |
| P/E at the last close | 15.1× | 27.3× |
| Insider trades, last 12 months | sold $508.7 million | sold $13.7 million |
| Piotroski F-score | 6 of 8 | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
DaVitaLabcorp
Operating margin
Percent of revenue
DaVitaLabcorp
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
DaVitaLabcorp